Meta‐Analysis: <scp>PPAR</scp> Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis
PPAR agonists, notably bezafibrate and seladelpar, reduce pruritus severity in PBC patients with moderate-to-severe symptoms and consistently improve itch-specific outcomes. However, effects on global HRQoL remain uncertain. These findings underscore the incorporation of validated, symptom-focused endpoints in future PBC trials.
Authors
- Nidah S. Khakoo (ORCID: https://orcid.org/0000-0003-2561-3826)
- John M. Reynolds (ORCID: https://orcid.org/0000-0003-4766-8852)
- Alexandra Rousseau
- Andreas Emanuel Kremer (ORCID: https://orcid.org/0000-0002-9263-948X)
- Adrielly Martins (ORCID: https://orcid.org/0000-0002-2653-2238)
- C. Corpéchot
- Cynthia Levy
- M. Hassan Murad
- Shahnaz Sultan
Institutions
- Mayo Clinic (US)
- University of Miami (US)
- Emory University (US)
- Inserm (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- University Hospital of Zurich (CH)
- Hôpital Saint-Antoine (FR)
- Mayo Clinic in Arizona (US)
- Centre de Recherche Saint-Antoine (FR)
- University of Minnesota Medical Center (US)
- Minneapolis VA Medical Center (US)
- Mayo Clinic in Florida (US)
- Florida Memorial University (US)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1111/apt.70634
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 0.00